In NSCLC patients with a PD-L1 TPS ≥50% and without EGFR or ALK mutations treated with pembrolizumab, those with a dNLR <2.6 had a significantly improved ORR, median PFS, and median OS compared with those with a dNLR ≥2.6 (116). This evidence concerns the gene EGFR and non-small cell lung carcinoma.